Boron in drug design: Recent advances in the development of new therapeutic agents
Top Cited Papers
- 1 October 2019
- journal article
- review article
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 179, 791-804
Abstract
No abstract availableKeywords
Funding Information
- Fundação de Amparo à Pesquisa do Estado de São Paulo
This publication has 94 references indexed in Scilit:
- Discovery of a Potent Boronic Acid Derived Inhibitor of the HCV RNA-Dependent RNA PolymeraseJournal of Medicinal Chemistry, 2013
- Boron‐based phosphodiesterase inhibitors show novel binding of boron to PDE4 bimetal centerFEBS Letters, 2012
- The pharmacological landscape and therapeutic potential of serine hydrolasesNature Reviews Drug Discovery, 2012
- SCYX-7158, an Orally-Active Benzoxaborole for the Treatment of Stage 2 Human African TrypanosomiasisPLOS Neglected Tropical Diseases, 2011
- Current Challenges in Antimicrobial ChemotherapyDrugs, 2010
- Discovery and structure–activity study of a novel benzoxaborole anti-inflammatory agent (AN2728) for the potential topical treatment of psoriasis and atopic dermatitisBioorganic & Medicinal Chemistry Letters, 2009
- The role of CXC chemokines and their receptors in cancerCancer Letters, 2008
- Structure-based optimization of cephalothin-analogue boronic acids as β-lactamase inhibitorsBioorganic & Medicinal Chemistry, 2008
- Boronic acid compounds as potential pharmaceutical agentsMedicinal Research Reviews, 2003
- Aminoacyl-tRNA Synthetases, the Genetic Code, and the Evolutionary ProcessMicrobiology and Molecular Biology Reviews, 2000